Cancer Clinical Trials
This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.
Trial Name: Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE).
Protocol ID: E1A11
Step 1 Randomization
Step 2 Randomization
The following patients will be excluded as this study involves an agent that may have genotoxic, mutagenic and teratogenic effects: pregnant women, nursing women.
Enrollment: 756 will be enrolled
Taking part in this study may or may not make your health better. While doctors hope the treatments used in the study will be more useful against cancer compared to the usual treatment, there is no proof of this yet. We do know that the information from this study will help doctors learn more about these drugs as a treatment for myeloma. This information could help future cancer patients.
These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Aspirus Regional Cancer Center Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353, or Langlade Cancer Center Research Nurse Debra Witman @ 715-623-9587.
Created: Feb 24, 2014
Updated: May 21, 2014